"10.1371_journal.pone.0091979","plos one","2014-03-17T00:00:00Z","Linda Kwakkenbos; Linda M Willems; Murray Baron; Marie Hudson; David Cella; Cornelia H M van den Ende; Brett D Thombs; and the Canadian Scleroderma Research Group","Department of Psychiatry, McGill University, Montréal, Québec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada; Department of Rheumatology, Sint Maartenskliniek Nijmegen, The Netherlands; Department of Medicine, McGill University, Montréal, Québec, Canada; Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America; Departments of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada; Educational and Counselling Psychology, McGill University, Montréal, Québec, Canada; Psychology, McGill University, Montréal, Québec, Canada; School of Nursing, McGill University, Montréal, Québec, Canada","¶ Membership of the Canadian Scleroderma Research Group is provided in the Acknowledgments.","We would like to confirm that co-author Dr. Brett D. Thombs is a PLOS ONE Editorial Board Member. This does not alter our adherence to PLOS ONE Editorial policies and criteria. We have the following interests. INOVA Diagnostics Inc. (San Diego, CA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Pfizer and Actelion pharmaceuticals have provided unrestricted educational and research funds to the Canadian Scleroderma Research Group. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","03","Linda Kwakkenbos","LK",8,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
